Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2015
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinitiesJian Zhang, Yen K Lieu, Abdullah M Ali, et al.
Leukemia Research|March 22, 2003
A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISHBetty Gladstone, Smitha Sivaraman, Naomi Galili, et al.
Cytometry. Part B, Clinical Cytometry|October 16, 2013
A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow FailureAzra Raza, Farhad Ravandi, Anjay Rastogi, et al.
Cytometry. Part B, Clinical Cytometry|November 15, 2013
A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failureAzra Raza, Farhad Ravandi, Anjay Rastogi, et al.
Blood|April 29, 2009
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Scott Smith, et al.
Medical Oncology (Northwood, London, England)|June 14, 2023
Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)Abdullah Mahmood Ali, Fatima BenMohamed, Alessandra Decina, et al.
Cancer Research|October 15, 2009
Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK networkSayyed K Zaidi, Christopher R Dowdy, Andre J van Wijnen, et al.
British Journal of Haematology|March 12, 2002
Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patientsVilasini Shetty, Seema Hussaini, Sairah Alvi, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Plos Medicine|February 15, 2008
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndromeBenjamin L Ebert, Naomi Galili, Pablo Tamayo, et al.
Pageof 10